Ivana Magovčević-Liebisch, Vigil CEO (file photo)
December 8, 2020 08:18 AM ESTUpdated 08:29 AM
Financing
Startups

Vig­il Neu­ro­science launch­es with a $50M Se­ries A and two for­mer Am­gen neu­ro­science can­di­dates

Nicole DeFeudis

Editor

Af­ter more than 20 years in the in­dus­try, Ivana Magov­če­vić-Liebisch had done it all — ex­cept build a com­pa­ny from scratch. Then Bruce Booth at At­las …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times